MARKET

QUIT

QUIT

Achieve Life Sciences Inc
NASDAQ
6.40
-0.38
-5.60%
After Hours: 6.30 -0.1 -1.56% 19:30 11/10 EST
OPEN
6.64
PREV CLOSE
6.78
HIGH
6.78
LOW
6.11
VOLUME
647.47K
TURNOVER
--
52 WEEK HIGH
8.64
52 WEEK LOW
2.620
MARKET CAP
658.58M
P/E (TTM)
-4.1405
1D
5D
1M
3M
1Y
5Y
1D
AchieveRx Reports Q3 Results; Cytisinicline NDA Resubmission On Track For Q4 2026
NASDAQ · 12h ago
Achieve Life Sciences reports Q3 results
Seeking Alpha · 16h ago
Achieve Life Sciences rebrands to AchieveRx
TipRanks · 1d ago
*Achieve Life Sciences Becomes AchieveRx, the Quit Company, To Trade Under Ticker QUIT
Dow Jones · 1d ago
Weekly Report: what happened at ACHV last week (1102-1106)?
Weekly Report · 1d ago
Achieve Life Sciences' Resubmission Timeline Depends on a Factory It Doesn't Control
Barchart · 6d ago
Weekly Report: what happened at ACHV last week (1026-1030)?
Weekly Report · 11/02 09:14
Weekly Report: what happened at ACHV last week (1019-1023)?
Weekly Report · 10/26 09:14
More
About QUIT
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: QUIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QUIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QUIT stock methods without spending real money on the virtual paper trading platform.